OncologyOnline.net

Oncology Xagena

Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced urothelial cancer ( also known as bladder cancer ) presented at ESMO ( European Society f ...


Data on the investigational use of Pembrolizumab ( Keytruda ), an anti-PD-1 agent, in PD-L1 positive, advanced gastric cancer were presented during the ESMO ( European Society for Medical Oncology ) 2 ...


Data from the coBRIM phase III study were presented at ESMO ( European Society of Medical Oncology ) 2014 Congress. The results have shown that people with previously untreated BRAF V600 mutation-po ...


The results from CheckMate -037, a phase 3 randomized, controlled open-label study of Nivolumab ( Opdivo ), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemothera ...


The U.S. Food and Drug Administration ( FDA ) has approved Keytruda ( Pembrolizumab ) at a dose of 2 mg/kg every three weeks for the treatment of patients with unresectable or metastatic melanoma and ...


Treatment outcomes for older patients with acute myeloid leukemia ( AML ) have remained dismal. A randomized, phase 2 trial in AML patients not considered suitable for intensive induction therapy comp ...


The combination of stent insertion and single high-dose brachytherapy is a feasible and safe palliative treatment regimen in patients with unresectable oesophageal cancer. A study has assessed the e ...


Advanced colorectal cancer is treated with a combination of cytotoxic drugs and targeted treatments. However, how best to minimise the time spent taking cytotoxic drugs and whether molecular selection ...


The prevention of medullary thyroid cancer in patients with multiple endocrine neoplasia ( MEN ) type 2 syndrome has demonstrated the ability of molecular diagnosis and prophylactic surgery to improve ...


Bevacizumab ( Avastin ), a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. A study has assessed the role of Bevacizumab as adjuvant treatment ...


In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with RAS mutations ( at exons 2, 3, and 4 ...


Ipilimumab ( Yervoy ) is a fully human monoclonal antibody that binds cytotoxic T-lymphocyte antigen 4 to enhance antitumour immunity. A study has assessed the use of Ipilimumab after radiotherapy i ...


Bone metastases frequently cause skeletal events in patients with metastatic castration-resistant prostate cancer. Radium-223 dichloride ( Radium-223 ) selectively targets bone metastases with high-en ...


An established multivariate serum protein test can be used to classify patients according to whether they are likely to have a good or poor outcome after treatment with EGFR tyrosine-kinase inhibitors ...


In the treatment of metastatic colorectal cancer, inferior overall survival, progression-free survival, and objective response rates have been shown in people with RAS mutations ( at exons 2, 3, and 4 ...


Current guidelines recommend both epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors ( TKIs ) and cytotoxic chemotherapy drugs as standard treatment options for patients with wild-ty ...


The combination of stent insertion and single high-dose brachytherapy is a feasible and safe palliative treatment regimen in patients with unresectable oesophageal cancer. A study has assessed the ...


Surgery for colorectal liver metastases results in an overall survival of about 40% at 5 years. Progression-free survival is increased with the addition of Oxaliplatin ( Eloxatin ) and Fluorouracil ( ...


Disease progression in patients with HER2-positive breast cancer receiving Trastuzumab ( Herceptin ) might be associated with activation of the PI3K/Akt/mTOR intracellular signalling pathway. Resear ...


Bisphosphonates are routinely used in the treatment of metastatic bone disease from breast cancer to reduce pain and bone destruction. Zoledronic acid ( Zometa ) given by intravenous infusion has been ...



2000-2014© XAGENA srl - P.IVA: 04454930969 - REA: 1748680 - Tutti i diritti riservati